Skip to main content

Advertisement

SpringerLink
Log in

MicroPET Imaging of Integrin αvβ3 Expressing Tumors Using 89Zr-RGD Peptides

  • Research Article
  • Published:
Molecular Imaging and Biology Aims and scope Submit manuscript

Abstract

Purpose

The dimeric transmembrane integrin, αvβ3, is a well-investigated target by different imaging modalities through suitably labeled arginine–glycine–aspartic acid (RGD) containing peptides. In this study, we labeled four cyclic RGD peptides with or without PEG functional groups: c(RGDfK) (denoted as FK), PEG3-c(RGDfK) (denoted as FK-PEG3), E[c(RGDfK)]2 (denoted as [FK]2), and PEG4-E[PEG4-c(RGDfK)]2 (denoted as [FK]2-3PEG4), with 89Zr (t 1/2 = 78.4 h), using the chelator desferrioxamine-p-SCN (Df) for imaging tumor integrin αvβ3.

Methods

The Df conjugated RGD peptides were subjected to integrin αvβ3 binding assay in vitro using MDA-MB-435 breast cancer cells. The 89Zr-labeled RGD peptides were then subjected to small animal positron emission tomography (PET) and direct tissue sampling biodistribution studies in an orthotopic MDA-MB-435 breast cancer xenograft model.

Results

All four tracers, 89Zr-Df-FK, 89Zr-Df-FK-PEG3, 89Zr-Df-[FK]2, and 89Zr-Df-[FK]2-3PEG4, were labeled in high radiochemical yield (89 ± 4%) and high specific activity (4.07–6 MBq/μg). Competitive binding assay with 125I-echistatin showed that conjugation of the RGD peptides to the Df chelator did not have significant impact on their integrin αvβ3 binding affinity and the dimeric peptides were shown to be more potent than the monomers. In agreement with binding results, tumor uptake of 89Zr-Df-[FK]2 and 89Zr-Df-[FK]2-3PEG4 was significantly higher (4.32 ± 1.73%ID/g and 4.72 ± 0.66%ID/g, respectively, at 2 h post-injection) than the monomers 89Zr-Df-FK and 89Zr-Df-FK-PEG3 (1.97 ± 0.38%ID/g and 1.57 ± 0.49%ID/g, respectively, at 2 h post-injection). Out of the four labeled peptides, 89Zr-Df-[FK]2-3PEG4 gave the highest tumor-to-background ratio (18.21 ± 2.52 at 2 h post-injection and 19.69 ± 3.99 at 4 h post-injection), with the lowest uptake in metabolic organs. Analysis of late time points biodistribution data revealed that the uptake in the tumor was decreased, along with increase in the bone, which implies decomplexation of 89Zr-Df.

Conclusion

Efficient radiolabeling of peptides with an appropriate chelator such as Df-RGD with 89Zr was observed. The 89Zr radiolabeled peptides provided high-quality and high-resolution microPET images in xenograft models. 89Zr-Df-[FK]2-3PEG4 demonstrated the highest tumor-to-background ratio of the compounds tested. Preparation of 89Zr peptides to take advantage of the longer half-life is unwarranted due to the relatively rapid clearance from the tumor region of peptide tracers prepared for this study and the increased uptake in the bone of transchelated 89Zr with time (2.0 ± 0.36%ID/g, 24 h post-injection).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Liu S (2009) Radiolabeled cyclic RGD peptides as integrin αvβ3-targeted radiotracers: maximizing binding affinity via bivalency. Bioconjug Chem 20:2199–2213

    Article  PubMed  CAS  Google Scholar 

  2. Carmeliet P, Jain RK (2000) Angiogenesis in cancer and other diseases. Nature 407:249–257

    Article  PubMed  CAS  Google Scholar 

  3. Carmeliet P (2000) Mechanisms of angiogenesis and arteriogenesis. Nat Med 6:389–395

    Article  PubMed  CAS  Google Scholar 

  4. Sengupta S, Chattopadhyay N, Mitra A, Ray S, Dasgupta S, Chatterjee A (2001) Role of αvβ3 integrin receptors in breast tumor. J Exp Clin Cancer Res 20:585–590

    PubMed  CAS  Google Scholar 

  5. Wang L, Shi J, Kim YS, Zhai S, Jia B, Zhao H et al (2009) Improving tumor-targeting capability and pharmacokinetics of 99mTc-labeled cyclic RGD dimers with PEG4 linkers. Mol Pharm 6:231–245

    Article  PubMed  CAS  Google Scholar 

  6. Chen X, Park R, Hou Y, Khankaldyyan V, Gonzales-Gomez I, Tohme M et al (2004) MicroPET imaging of brain tumor angiogenesis with 18F-labeled PEGylated RGD peptide. Eur J Nucl Med Mol Imaging 31:1081–1089

    Article  PubMed  CAS  Google Scholar 

  7. Chen X, Liu S, Hou Y, Tohme M, Park R, Bading JR et al (2004) MicroPET imaging of breast cancer αv-integrin expression with 64Cu-labeled dimeric RGD peptides. Mol Imaging Biol 6:350–359

    Article  PubMed  Google Scholar 

  8. Chen X, Tohme M, Park R, Hou Y, Bading JR, Conti PS (2004) Micro-PET imaging of αvβ3-integrin expression with 18F-labeled dimeric RGD peptide. Mol Imaging 3:96–104

    Article  PubMed  CAS  Google Scholar 

  9. Dijkgraaf I, Beer AJ, Wester HJ (2009) Application of RGD-containing peptides as imaging probes for αvβ3 expression. Front Biosci 14:887–899

    Article  PubMed  CAS  Google Scholar 

  10. Bello L, Francolini M, Marthyn P, Zhang J, Carroll RS, Nikas DC et al (2001) αvβ3 and αvβ5 integrin expression in glioma periphery. Neurosurgery 49:380–389, discussion 90

    PubMed  CAS  Google Scholar 

  11. Felding-Habermann B, Mueller BM, Romerdahl CA, Cheresh DA (1992) Involvement of integrin αv gene expression in human melanoma tumorigenicity. J Clin Invest 89:2018–2022

    Article  PubMed  CAS  Google Scholar 

  12. Robinson SD, Reynolds LE, Wyder L, Hicklin DJ, Hodivala-Dilke KM (2004) β3-integrin regulates vascular endothelial growth factor-A-dependent permeability. Arterioscler Thromb Vasc Biol 24:2108–2114

    Article  PubMed  CAS  Google Scholar 

  13. Zhang X, Xiong Z, Wu Y, Cai W, Tseng JR, Gambhir SS et al (2006) Quantitative PET imaging of tumor integrin αvβ3 expression with 18F-FRGD2. J Nucl Med 47:113–121

    PubMed  CAS  Google Scholar 

  14. Chen X (2006) Multimodality imaging of tumor integrin αvβ3 expression. Mini Rev Med Chem 6:227–234

    Article  PubMed  CAS  Google Scholar 

  15. Cai W, Niu G, Chen X (2008) Imaging of integrins as biomarkers for tumor angiogenesis. Curr Pharm Des 14:2943–2973

    Article  PubMed  CAS  Google Scholar 

  16. Liu S (2006) Radiolabeled multimeric cyclic RGD peptides as integrin αvβ3 targeted radiotracers for tumor imaging. Mol Pharm 3:472–487

    Article  PubMed  CAS  Google Scholar 

  17. Bogler O, Mikkelsen T (2003) Angiogenesis in glioma: molecular mechanisms and roadblocks to translation. Cancer J 9:205–213

    Article  PubMed  Google Scholar 

  18. Hwang R, Varner J (2004) The role of integrins in tumor angiogenesis. Hematol Oncol Clin North Am 18:991–1006, vii

    Article  PubMed  Google Scholar 

  19. Brooks PC, Montgomery AM, Rosenfeld M, Reisfeld RA, Hu T, Klier G et al (1994) Integrin αvβ3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 79:1157–1164

    Article  PubMed  CAS  Google Scholar 

  20. Brooks PC, Clark RA, Cheresh DA (1994) Requirement of vascular integrin αvβ3 for angiogenesis. Science 264:569–571

    Article  PubMed  CAS  Google Scholar 

  21. Dayton PA, Pearson D, Clark J, Simon S, Schumann PA, Zutshi R et al (2004) Ultrasonic analysis of peptide- and antibody-targeted microbubble contrast agents for molecular imaging of αvβ3-expressing cells. Mol Imaging 3:125–134

    Article  PubMed  CAS  Google Scholar 

  22. Ellegala DB, Leong-Poi H, Carpenter JE, Klibanov AL, Kaul S, Shaffrey ME et al (2003) Imaging tumor angiogenesis with contrast ultrasound and microbubbles targeted to αvβ3. Circulation 108:336–341

    Article  PubMed  Google Scholar 

  23. Leong-Poi H, Christiansen J, Klibanov AL, Kaul S, Lindner JR (2003) Noninvasive assessment of angiogenesis by ultrasound and microbubbles targeted to αv-integrins. Circulation 107:455–460

    Article  PubMed  CAS  Google Scholar 

  24. Sipkins DA, Cheresh DA, Kazemi MR, Nevin LM, Bednarski MD, Li KC (1998) Detection of tumor angiogenesis in vivo by αvβ3-targeted magnetic resonance imaging. Nat Med 4:623–626

    Article  PubMed  CAS  Google Scholar 

  25. Chen X, Conti PS, Moats RA (2004) In vivo near-infrared fluorescence imaging of integrin αvβ3 in brain tumor xenografts. Cancer Res 64:8009–8014

    Article  PubMed  CAS  Google Scholar 

  26. Chen X, Park R, Shahinian AH, Tohme M, Khankaldyyan V, Bozorgzadeh MH et al (2004) 18F-labeled RGD peptide: initial evaluation for imaging brain tumor angiogenesis. Nucl Med Biol 31:179–189

    Article  PubMed  CAS  Google Scholar 

  27. Chen X, Park R, Tohme M, Shahinian AH, Bading JR, Conti PS (2004) MicroPET and autoradiographic imaging of breast cancer αv-integrin expression using 18F- and 64Cu-labeled RGD peptide. Bioconjug Chem 15:41–49

    Article  PubMed  Google Scholar 

  28. Chen X, Park R, Shahinian AH, Bading JR, Conti PS (2004) Pharmacokinetics and tumor retention of 125I-labeled RGD peptide are improved by PEGylation. Nucl Med Biol 31:11–19

    Article  PubMed  CAS  Google Scholar 

  29. Chen X, Hou Y, Tohme M, Park R, Khankaldyyan V, Gonzales-Gomez I et al (2004) Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor αvβ3-integrin expression. J Nucl Med 45:1776–1783

    PubMed  CAS  Google Scholar 

  30. Haubner R, Wester HJ, Weber WA, Mang C, Ziegler SI, Goodman SL et al (2001) Noninvasive imaging of αvβ3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res 61:1781–1785

    PubMed  CAS  Google Scholar 

  31. Haubner R, Bruchertseifer F, Bock M, Kessler H, Schwaiger M, Wester HJ (2004) Synthesis and biological evaluation of a 99mTc-labelled cyclic RGD peptide for imaging the αvβ3 expression. Nuklearmedizin 43:26–32

    PubMed  CAS  Google Scholar 

  32. Haubner R, Kuhnast B, Mang C, Weber WA, Kessler H, Wester HJ et al (2004) [18F]Galacto-RGD: synthesis, radiolabeling, metabolic stability, and radiation dose estimates. Bioconjug Chem 15:61–69

    Article  PubMed  CAS  Google Scholar 

  33. Li ZB, Chen K, Chen X (2008) 68Ga-labeled multimeric RGD peptides for microPET imaging of integrin αvβ3 expression. Eur J Nucl Med Mol Imaging 35:1100–1108

    Article  PubMed  CAS  Google Scholar 

  34. Wu Z, Li ZB, Chen K, Cai W, He L, Chin FT et al (2007) microPET of tumor integrin αvβ3 expression using 18F-labeled PEGylated tetrameric RGD peptide (18F-FPRGD4). J Nucl Med 48:1536–1544

    Article  PubMed  CAS  Google Scholar 

  35. Holland JP, Sheh Y, Lewis JS (2009) Standardized methods for the production of high specific-activity zirconium-89. Nucl Med Biol 36:729–739

    Article  PubMed  CAS  Google Scholar 

  36. Vosjan MJ, Perk LR, Visser GW, Budde M, Jurek P, Kiefer GE et al (2010) Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p-isothiocyanatobenzyl-desferrioxamine. Nat Protoc 5:739–743

    Article  PubMed  CAS  Google Scholar 

  37. Wu Y, Zhang X, Xiong Z, Cheng Z, Fisher DR, Liu S et al (2005) microPET imaging of glioma integrin αvβ3 expression using 64Cu-labeled tetrameric RGD peptide. J Nucl Med 46:1707–1718

    PubMed  CAS  Google Scholar 

  38. Janssen M, Oyen WJ, Massuger LF, Frielink C, Dijkgraaf I, Edwards DS et al (2002) Comparison of a monomeric and dimeric radiolabeled RGD-peptide for tumor targeting. Cancer Biother Radiopharm 17:641–646

    Article  PubMed  CAS  Google Scholar 

  39. Haubner R, Wester HJ, Reuning U, Senekowitsch-Schmidtke R, Diefenbach B, Kessler H et al (1999) Radiolabeled αvβ3 integrin antagonists: a new class of tracers for tumor targeting. J Nucl Med 40:1061–1071

    PubMed  CAS  Google Scholar 

  40. Dijkers EC, Oude Munnink TH, Kosterink JG, Brouwers AH, Jager PL, de Jong JR et al (2010) Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin Pharmacol Ther 87:586–592

    Article  PubMed  CAS  Google Scholar 

  41. Tinianow JN, Gill HS, Ogasawara A, Flores JE, Vanderbilt AN, Luis E et al (2010) Site-specifically 89Zr-labeled monoclonal antibodies for ImmunoPET. Nucl Med Biol 37:289–297

    Article  PubMed  CAS  Google Scholar 

  42. Hoeben BA, Kaanders JH, Franssen GM, Troost EG, Rijken PF, Oosterwijk E et al (2010) PET of hypoxia with 89Zr-labeled cG250-F(ab′)2 in head and neck tumors. J Nucl Med 51:1076–1083

    Article  PubMed  CAS  Google Scholar 

  43. Holland JP, Divilov V, Bander NH, Smith-Jones PM, Larson SM, Lewis JS (2010) 89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo. J Nucl Med 51:1293–1300

    Article  PubMed  CAS  Google Scholar 

  44. Shi J, Kim YS, Zhai S, Liu Z, Chen X, Liu S (2009) Improving tumor uptake and pharmacokinetics of 64Cu-labeled cyclic RGD peptide dimers with Gly3 and PEG4 linkers. Bioconjug Chem 20:750–759

    Article  PubMed  CAS  Google Scholar 

  45. Meijs WE, Herscheid JDM, Haisma H, Pinedo HM (1992) Evaluation of desferal as a bifunctional chelating agent for labeling antibodies with Zr-89. Appl Radiat Isot 43:1443–1447

    Article  CAS  Google Scholar 

Download references

Acknowledgment

This research was supported by the Intramural Research Program (IRP) of the National Institute of Biomedical Imaging and Bioengineering (NIBIB).

Conflict of Interest Statement

Authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Laboratory of Molecular Imaging and Nanomedicine (LOMIN), National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institutes of Health (NIH), Bldg. 31, Room 1C22, Bethesda, MD, 20892, USA

    Orit Jacobson, Lei Zhu, Gang Niu, Ying Ma, Xilin Sun, Yongjun Yan, Dale O. Kiesewetter & Xiaoyuan Chen

  2. Key Laboratory for Molecular Enzymology and Enzyme Engineering of the Ministry of Education, Jilin University, Jilin, 130000, China

    Lei Zhu

  3. Laboratory of Molecular Immunology, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA

    Ido D. Weiss

  4. Department of Positron Emission Tomography, Warren Grant Magnuson Clinical Center, National Institutes of Health, Bethesda, MD, USA

    Lawrence P. Szajek

  5. School of Health Sciences, Purdue University, West Lafayette, IN, USA

    Shuang Liu

Authors
  1. Orit Jacobson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lei Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gang Niu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ido D. Weiss
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Lawrence P. Szajek
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ying Ma
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Xilin Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Yongjun Yan
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Dale O. Kiesewetter
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Shuang Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Xiaoyuan Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Xiaoyuan Chen.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jacobson, O., Zhu, L., Niu, G. et al. MicroPET Imaging of Integrin αvβ3 Expressing Tumors Using 89Zr-RGD Peptides. Mol Imaging Biol 13, 1224–1233 (2011). https://doi.org/10.1007/s11307-010-0458-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11307-010-0458-y

Key words

Search

Navigation